Dermatology specialist Galderma (SWX:GALD) announced on Wednesday the launch of Restylane Defyne and Restylane Refyne in Japan, marking the first approval and commercialisation of Optimal Balance Technology (OBT) hyaluronic acid injectables in the country.

The products are indicated for injection into the mid-to-deep dermis to correct moderate to severe facial wrinkles and folds.

Restylane Defyne and Refyne are designed to balance softness, flexibility, and structural support, enabling natural facial movement while maintaining lift. Refyne targets delicate, highly expressive areas with a smooth, flexible gel, while Defyne provides enhanced support for areas such as the jawline and deeper facial folds. According to Galderma, these are the first and only hyaluronic acid injectables clinically proven to restore youthful facial expressions.

The launches expand Galderma's Restylane portfolio in Japan to four products, alongside Restylane Classyc and Restylane Lyft, broadening treatment options for clinicians. Approval was supported by two double-blinded, randomised, active-controlled Phase III studies involving 171 and 162 subjects, respectively, which demonstrated clinically meaningful wrinkle severity improvement for up to 12 months.